News
EDA, community partners fund ‘virtual hospital’ at the UT Health Science Center San Antonio
SAN ANTONIO - A $1 million grant from the Economic Development Administration (EDA) and funding from ...
National Trauma Institute Seeks To Stop The Bleeding With Dramatic Campaign In Times Square
(SAN ANTONIO) – The National Trauma Institute (NTI), a non-profit organization dedicated to funding ...
Events
16th Annual Trauma Symposium
16th Annual Trauma SymposiumAug. 30 – Sept. 1, 2010Marriott RivercenterSan Antonio, Texas A ...Save the Date for the Annual Julio Palmaz Award Dinner
Save The Date 5th Annual Julio Palmaz Award Dinner. Honoring a local biomedical innovator.Thursday, ...Industry Publications
The Mission
The Mission is published by the University of Texas Health Science Center.
UTSA Discovery
UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...
GenSpera Inc. has reached a milestone in the development of its investigational cancer drug.
In a phase 1 clinical study, doctors at the University of Wisconsin Carbone Cancer Center in Madison treated the first patient with GenSpera’s cancer chemotherapeutic agent G-202.
The phase 1 clinical study is designed to treat up to 30 patients with cancers that have progressed even after treatment with other anti-cancer therapies. The study will determine the safety, tolerability and effect the drug has on the human body. Researchers will also study how effective the drug is in treating solid tumors.
G-202 is designed to target the blood vessels in solid tumors in order to destroy the tumor’s blood supply.
San Antonio-based GenSpera is a development stage oncology company.
